CureVac (CVAC)

• Market cap: $1.17B
• 1 day: -0.76%
• 5 days: -2.07%
• 1 month: -4.05%
• 3 months: -4.58%
• 6 months: 50.14%
• Year to date: 51.01%
• 1 year: 84.1%
• 5 years: -90.47%
• 10 years: -90.68%
• Sector: Healthcare
• Industry: Biotechnology

About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,088